Exifone (Compound)

Synonyms:EXIFONE, 52479-85-3, 2,3,3',4,4',5'-Hexahydroxybenzophenone, Adlone, (2,3,4-Trihydroxyphenyl)(3,4,5-trihydroxyphenyl)methanone, 4-Galloylpyrogallol, Exifone [INN], (2,3,4-trihydroxyphenyl)-(3,4,5-trihydroxyphenyl)methanone, NSC 680919, NSC-680919, NSC680919, Methanone, (2,3,4-trihydroxyphenyl)(3,4,5-trihydroxyphenyl)-, 38K9TOD4EG, DTXSID9044950, DTXCID7024950, Exifona, Exifonum, Exifonum [INN-Latin], Exifona [INN-Spanish], CAS-52479-85-3, EINECS 257-945-9, UNII-38K9TOD4EG, BRN 3401917, EXIFONE [MI], EXIFONE [MART.], EXIFONE [WHO-DD], 3-08-00-04364 (Beilstein Handbook Reference), SCHEMBL273096, CHEMBL329522, CHEBI:125609, BDBM234394, Tox21_113656, Tox21_201450, Tox21_303559, MFCD00082966, AKOS015904176, CCG-208095, KS-5168, 2,3,3',4,4'-Hexahydrobenzoxyphenone, 3,4,5,2,3,4-Hexahydroxybenzophenone, NCGC00249050-01, NCGC00249050-02, NCGC00257438-01, NCGC00259001-01, 72841-23-7, DB-019631, 3,4,5,4',5',6'-hexahydroxy benzophenone, FT-0614115, H1065, H1783, 2,3,3\',4,4\',5\'-Hexahydroxybenzophenone, D91001, A829106, SR-01000944884, 2,3,3',4,4',5-HEXAHYDROXY-BENZOPHENONE, SR-01000944884-1, W-105820, BRD-K65716359-001-01-3, Q27216225, [2,3,4-trihydroxyphenyl] [3',4',5'-trihydroxyphenyl] methanone, [2,3,4-tris(oxidanyl)phenyl]-[3,4,5-tris(oxidanyl)phenyl]methanone
Id:40399

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Exifone's neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Exifone.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Exifone.

Results found

Linked to

 

Label

Description

 

Substance

A Substance

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.